Immune checkpoint inhibitor–associated orbital inflammation: a systematic review
Graefe's Archive for Clinical and Experimental Ophthalmology · 06.11.2026
DOI: 10.1007/s00417-026-07589-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, online erschienen am 06.11.2026. Verfasst von Jai E Paris und 6 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Ophthalmology and Vision Sciences, University of Adelaide, Adelaide, Australia. Jai.paris@adelaide.edu.au. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adelaide University.
Abstract (Originalsprache)
Purpose
Immune checkpoint inhibitors (ICIs) are increasingly used across a growing range of malignancies. ICI-associated orbital inflammation is a rare immune-related adverse event (irAE) that remains poorly characterised despite its potential for substantial visual morbidity.
Methods
A systematic search of PubMed, Ovid MEDLINE, Embase, Scopus, and Google Scholar was performed in September 2026. Studies reporting orbital inflammatory disease during or following ICI therapy were included.
Results
Fifty-seven studies reporting 81 patients were included. The median age at presentation was 65.6 years (IQR, 55.5–77.0), and 63% were male. Melanoma was the most common malignancy (40.7%). The median time to onset of orbital inflammation following ICI initiation was 6.0 weeks (IQR, 3.5–11.3). Concurrent non-orbital irAEs occurred in 67.9% of patients, most commonly systemic myositis (37.0%) and myocarditis (23.5%). The most common clinical features were ophthalmoplegia (70.4%) and proptosis (29.6%), with bilateral disease in 76.5% of cases. Extraocular muscle inflammation predominated (82.7%), followed by diffuse orbital inflammation (32.1%), while dacryoadenitis (4.9%) and optic nerve involvement (6.2%) were rare. Thyroid eye disease–like orbitopathy was described in 17.3% of patients, most of whom were euthyroid (78.6%). Corticosteroids were administered in 92.6% of patients, with 39.5% requiring additional immunomodulatory therapy. Complete or partial resolution occurred in 88.3% of patients and disease recurrence occurred in 9.9%.
Conclusions
ICI-associated orbital inflammation demonstrates a distinct phenotype characterised by early onset, bilateral disease, extraocular muscle predominance, and frequent overlap with systemic myositis and myocarditis. Recognition should prompt immediate multidisciplinary assessment and evaluation for systemic irAEs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Discipline of Ophthalmology and Vision Sciences, University of Adelaide, Adelaide, Australia. Jai.paris@adelaide.edu.au.
- Discipline of Ophthalmology and Vision Sciences, University of Adelaide, Adelaide, Australia.
- South Australian Institute of Ophthalmology, Royal Adelaide Hospital, Adelaide, Australia.
- Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
- Flinders Eye Centre Clinic, Flinders Drive, Bedford Park, South Australia.
Förderung
- Adelaide University
Zitieren
APA
Paris, J. E., La, E., Agarwal, A., Tong, J. Y., Slattery, J., Chan, W. O., & Selva, D. (2026). Immune checkpoint inhibitor–associated orbital inflammation: a systematic review. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-026-07589-3
Vancouver
Paris JE, La E, Agarwal A, Tong JY, Slattery J, Chan WO, et al. Immune checkpoint inhibitor–associated orbital inflammation: a systematic review. Graefe's Archive for Clinical and Experimental Ophthalmology. 2026. doi:10.1007/s00417-026-07589-3
BibTeX
@article{Paris2026,
author = {Paris, Jai E and La, Ethan and Agarwal, Ayushi and Tong, Jessica Y and Slattery, James and Chan, Weng Onn and Selva, Dinesh},
title = {Immune checkpoint inhibitor–associated orbital inflammation: a systematic review},
journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
year = {2026},
doi = {10.1007/s00417-026-07589-3}
}
EUVIMED